NDA 022556 · Aytu
Karbinal Er
Carbinoxamine Maleate · Oral
Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Mar 28, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
157
77 serious, 29 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 12, 2026.
Carbinoxamine Maleate extended-release oral suspension is indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: Seasonal and perennial allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled Amelioration of the severity of allergic reactions to blood or plasma Carbinoxamine Maleate extended-release oral suspension is an H1 receptor antagonist indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: Seasonal and perennial allergic rhinitis ( 1 ) Vasomotor rhinitis ( 1 ) Allergic conjunctivitis due to inhalant allergens and foods ( 1 ) Mild, uncomplicated allergic skin manifestations of urticaria and angioedema ( 1 ) Dermatographism (1) As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled ( 1 ) Amelioration of the severity of allergic reactions to blood or plasma ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 28, 2013 Original approval · Type 3 - New Dosage Form Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewLetter
1 products under this application
- KARBINAL ER · CARBINOXAMINE MALEATE 4MG/5ML · SUSPENSION, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Carbinoxamine" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug toxicity14
- drug ineffective9
- headache9
- pain8
- pyrexia8
- dizziness7
- fatigue7
- sinusitis7
- unresponsive to stimuli7
- urticaria7
- vomiting7
- anxiety6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 3 |
| 2006 | 6 |
| 2007 | 6 |
| 2008 | 6 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 5 |
| 2016 | 9 |
| 2017 | 11 |
| 2018 | 12 |
| 2019 | 6 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 15 |
| 2023 | 6 |
| 2024 | 8 |
| 2025 | 13 |
| 2026 | 11 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Chronic sinusitis in children with respiratory allergy: the role of antimicrobials.
Rachelefsky GS, Katz RM, Siegel SC · J Allergy Clin Immunol 1982 · Clinical Trial, Controlled Clinical Trial
- Efficacy of a timed-release antihistamine/decongestant tablet for symptoms of nasal allergy.
Connell JT, Gold AJ, Zola EM, et al. · Drug Intell Clin Pharm 1984 · Clinical Trial, Randomized Controlled Trial
- Relative bioavailability of carbinoxamine and phenylephrine from a retard capsule after single and repeated dose administration in healthy subjects.
Stockis A, Deroubaix X, Jeanbaptiste B, et al. · Arzneimittelforschung 1995 · Clinical Trial, Randomized Controlled Trial
- [Serous otitis media. Comparative study of carbinoxamine- pseudoephedrine vs astemizole-pseudoephedrine].
Pérez Carmona NJ, García MA, Fuentes Rejón T · Rev Alerg Mex 1997 · Clinical Trial, Comparative Study
- Single and repeated dose comparison of three antihistamines and phenylpropanolamine: psychomotor performance and subjective appraisals of sleep.
Seppälä T, Nuotto E, Korttila K · Br J Clin Pharmacol 1981 · Clinical Trial, Comparative Study
Sponsor: Aytu
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.